(Q39062353)

8 September 2017

Selective histone deacetylase small molecule inhibitors: recent progress and perspectives (English)

1 reference

8 September 2017

Hai-Tao Qin

1

1 reference

8 September 2017

Huan-Qiu Li

series ordinal

2

1 reference

8 September 2017

Feng Liu

series ordinal

3

1 reference

8 September 2017

language of work or name

English

0 references

publication date

29 December 2016

1 reference

Expert Opinion on Therapeutic Patents

8 September 2017

1 reference

8 September 2017

27

1 reference

8 September 2017

5

1 reference

8 September 2017

621-636

1 reference

Translating the Histone Code

8 September 2017

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Acetylation and deacetylation of non-histone proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Histone deacetylation in epigenetics: an attractive target for anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Histone deacetylase inhibitors: from bench to clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Histone deacetylases and cancer: causes and therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

The Sir2 family of protein deacetylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Histone deacetylases (HDACs): characterization of the classical HDAC family

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Negative and positive regulation of gene expression by mouse histone deacetylase 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Essential function of histone deacetylase 1 in proliferation control and CDK inhibitor repression

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Histone deacetylases 1 and 2 redundantly regulate cardiac morphogenesis, growth, and contractility

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Class II histone deacetylases act as signal-responsive repressors of cardiac hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Intracellular trafficking of histone deacetylase 4 regulates neuronal cell death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Phase I study of chidamide (CS055/HBI-8000), a new histone deacetylase inhibitor, in patients with advanced solid tumors and lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Mechanism of sirtuin inhibition by nicotinamide: altering the NAD(+) cosubstrate specificity of a Sir2 enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Epigenetic therapies for non-oncology indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Synthesis and conformation-activity relationships of the peptide isosteres of FK228 and largazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Structure and activity of largazole, a potent antiproliferative agent from the Floridian marine cyanobacterium Symploca sp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Romidepsin for the treatment of cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Largazole and analogues with modified metal-binding motifs targeting histone deacetylases: synthesis and biological evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Synthesis and biological characterization of the histone deacetylase inhibitor largazole and C7- modified analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Biological evaluation of new largazole analogues: alteration of macrocyclic scaffold with click chemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Total synthesis of largazole and analogues: HDAC inhibition, antiproliferative activity and metabolic stability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Synthesis and biological evaluation of c7-demethyl largazole analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Genomewide studies of histone deacetylase function in yeast

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Creation of a histone deacetylase 6 inhibitor and its biological effects [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Belinostat in patients with refractory or relapsed peripheral T-cell lymphoma: a perspective review

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Structural Biasing Elements for In-Cell Histone Deacetylase Paralog Selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Rational design and simple chemistry yield a superior, neuroprotective HDAC6 inhibitor, tubastatin A

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Second-generation histone deacetylase 6 inhibitors enhance the immunosuppressive effects of Foxp3+ T-regulatory cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Design and synthesis of orally bioavailable aminopyrrolidinone histone deacetylase 6 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

HDAC6 as a target for antileukemic drugs in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Quinazolin-4-one derivatives as selective histone deacetylase-6 inhibitors for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Selective histone deacetylase 6 inhibitors bearing substituted urea linkers inhibit melanoma cell growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Isoxazole moiety in the linker region of HDAC inhibitors adjacent to the Zn-chelating group: effects on HDAC biology and antiproliferative activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Synthesis and Biological Investigation of Oxazole Hydroxamates as Highly Selective Histone Deacetylase 6 (HDAC6) Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Identification of novel, selective, and stable inhibitors of class II histone deacetylases. Validation studies of the inhibition of the enzymatic activity of HDAC4 by small molecules as a novel approach for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Non-peptide macrocyclic histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Novel N-hydroxyfurylacrylamide-based histone deacetylase (HDAC) inhibitors with branched CAP group (Part 2).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Synthesis and biological evaluation of ortho-aryl N-hydroxycinnamides as potent histone deacetylase (HDAC) 8 isoform-selective inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Discovery of histone deacetylase 8 selective inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Synthesis and biological evaluation of N-hydroxyphenylacrylamides and N-hydroxypyridin-2-ylacrylamides as novel histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Rapid discovery of highly potent and selective inhibitors of histone deacetylase 8 using click chemistry to generate candidate libraries

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Design, synthesis and preliminary activity assay of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives as novel Histone deacetylases (HDACs) inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Development of tetrahydroisoquinoline-based hydroxamic acid derivatives: potent histone deacetylase inhibitors with marked in vitro and in vivo antitumor activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Design, synthesis, and antitumor evaluation of novel histone deacetylase inhibitors equipped with a phenylsulfonylfuroxan module as a nitric oxide donor

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Discovery of the first N-hydroxycinnamamide-based histone deacetylase 1/3 dual inhibitors with potent oral antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Histone deacetylase inhibitors with enhanced enzymatic inhibition effects and potent in vitro and in vivo antitumor activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Panobinostat: a novel pan-deacetylase inhibitor for the treatment of relapsed or relapsed and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Discovery of N-(2-aminophenyl)-4-[(4-pyridin-3-ylpyrimidin-2-ylamino)methyl]benzamide (MGCD0103), an orally active histone deacetylase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Entinostat for treatment of solid tumors and hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Acquired vorinostat resistance shows partial cross-resistance to 'second-generation' HDAC inhibitors and correlates with loss of histone acetylation and apoptosis but not with altered HDAC and HAT activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

In vivo destabilization of dynamic microtubules by HDAC6-mediated deacetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Chidamide, a novel histone deacetylase inhibitor, synergistically enhances gemcitabine cytotoxicity in pancreatic cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Development of frataxin gene expression measures for the evaluation of experimental treatments in Friedreich's ataxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Inhibition of histone deacetylase 3 causes replication stress in cutaneous T cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

HDAC3-selective inhibitor enhances extinction of cocaine-seeking behavior in a persistent manner

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Potent and Selective Inhibitors of Histone Deacetylase-3 Containing Chiral Oxazoline Capping Groups and a N-(2-Aminophenyl)-benzamide Binding Unit

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Santacruzamate A, a potent and selective histone deacetylase inhibitor from the Panamanian marine cyanobacterium cf. Symploca sp

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

HDAC6 is a target for protection and regeneration following injury in the nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Chiral Mercaptoacetamides Display Enantioselective Inhibition of Histone Deacetylase 6 and Exhibit Neuroprotection in Cortical Neuron Models of Oxidative Stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

A novel class of small molecule inhibitors of HDAC6.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Sirtuin catalysis and regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

The 2.5 Å crystal structure of the SIRT1 catalytic domain bound to nicotinamide adenine dinucleotide (NAD+) and an indole (EX527 analogue) reveals a novel mechanism of histone deacetylase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Discovery of thieno[3,2-d]pyrimidine-6-carboxamides as potent inhibitors of SIRT1, SIRT2, and SIRT3

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Selective Sirt2 inhibition by ligand-induced rearrangement of the active site.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

Histone Deacetylase Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13543776.2017.1276565

10.1080/13543776.2017.1276565

21 January 2018

Identifiers

DOI

1 reference

8 September 2017

1 reference